[CH3:1][O:2][C:3]1[CH:4]=[C:5]([C:11]2[S:15][C:14]3=[N:16][CH:17]=[C:18](I)[N:13]3[N:12]=2)[CH:6]=[CH:7][C:8]=1[O:9][CH3:10].[C:20]([O:24][C:25]([N:27]1[CH2:32][CH2:31][N:30]([C:33]2[C:38]([C:39]([F:42])([F:41])[F:40])=[CH:37][C:36](B3OC(C)(C)C(C)(C)O3)=[CH:35][N:34]=2)[CH2:29][CH2:28]1)=[O:26])([CH3:23])([CH3:22])[CH3:21].C([O-])([O-])=O.[Na+].[Na+]>O1CCOCC1>[C:20]([O:24][C:25]([N:27]1[CH2:28][CH2:29][N:30]([C:33]2[C:38]([C:39]([F:42])([F:40])[F:41])=[CH:37][C:36]([C:18]3[N:13]4[C:14]([S:15][C:11]([C:5]5[CH:6]=[CH:7][C:8]([O:9][CH3:10])=[C:3]([O:2][CH3:1])[CH:4]=5)=[N:12]4)=[N:16][CH:17]=3)=[CH:35][N:34]=2)[CH2:31][CH2:32]1)=[O:26])([CH3:23])([CH3:21])[CH3:22]A mixture of 2-(3,4-dimethoxy-phenyl)-5-iodo-imidazo[2,1-b][1,3,4]thiadiazole (0.2 g, 0.517 mmol, 1 eq), PdCl2(Ph3P)2 (73 mg, 0.103 mmol, 0.2 eq), 4-[5-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-3-trifluoromethyl-pyridin-2-yl]-piperazine-1-carboxylic acid tert-butyl ester (0.354 g, 0.775 mmol, 1.5 eq) and Na2CO3 (2M aqueous solution, 1 mL) in dioxane (4 mL) was heated at 110° C. for 2.5 h. The reaction was cooled down to rt and solvents were removed under reduced pressure. The residue was treated with water, sonicated and filtered. The solid was washed with water and purified by column chromatography (Biotage, cHex/EtOac 10 to 100%) to afford the desired product (170 mg, 56%): HPLC-MS: (5-100% B in 8 min, 0.8 mL/min, 50° C.): tR=7.36 min, [M+H]+ m/z 591.2; 1H NMR (300 MHz, CDCl3) δ 8.98 (d, J=2.0 Hz, 1H), 8.56 (d, J=2.2 Hz, 1H), 7.62 (s, 1H), 7.42 (m, 2H), 6.95 (m, 1H), 3.98 (s, 3H), 3.96 (s, 3H), 3.57 (m, 4H), 3.31 (m, 4H), 1.50 (s, 9H).
読み込み中…